The Cost Challenge With Afrezza

Afrezza (insulin human inhalation powder) represents a significant therapeutic advance as the only FDA-approved inhaled insulin. However, its cost — typically $550 to $650 per prescription at cash price, with no generic alternative available — creates a real barrier to adherence for many patients. As prescribers, we play a critical role in helping patients navigate the financial landscape so that cost does not undermine clinical outcomes.

This guide consolidates the key strategies providers can use to help patients access Afrezza affordably in 2026. For a companion piece focused on helping patients locate Afrezza when supply is limited, see How to Help Your Patients Find Afrezza in Stock.

Understanding the Insurance Landscape for Afrezza

Formulary Placement and Prior Authorization

Afrezza's formulary placement varies significantly across payers. Common scenarios include:

• Specialty tier placement — Many commercial plans place Afrezza on specialty tiers with higher cost-sharing (often 25-50% coinsurance rather than a fixed copay).
• Prior authorization requirements — Most plans require PA documentation showing medical necessity. Common PA criteria include documentation of inadequate glycemic control with injectable mealtime insulin, needle phobia, or injection site complications.
• Step therapy — Some plans require documented failure or intolerance of injectable rapid-acting insulin (insulin lispro, insulin aspart, or insulin glulisine) before covering Afrezza.
• Medicare Part D — Coverage varies by plan. Patients may face donut hole or coverage gap costs. The Inflation Reduction Act's insulin cost caps apply to insulin products, which may benefit Afrezza patients on Medicare.

Tips for Successful Prior Authorization

To improve PA approval rates, document the following in your clinical notes:

• Specific clinical rationale (e.g., needle phobia with documented non-adherence, lipodystrophy at injection sites, recurrent late postprandial hypoglycemia with injectable rapid-acting insulin)
• Prior trials of injectable mealtime insulins with dates and outcomes
• Current A1C and blood glucose data demonstrating need for mealtime insulin optimization
• Spirometry results confirming eligibility (FEV1 within acceptable range)

Having this documentation ready before the PA request significantly reduces denials and appeals.

MannKind's AfrezzaAssist Program

MannKind Corporation offers the AfrezzaAssist program, which provides multiple layers of financial support:

Co-Pay Savings Card

For commercially insured patients, the AfrezzaAssist co-pay card can reduce out-of-pocket costs at the pharmacy. Eligibility criteria and savings amounts vary — direct patients to the program website or have your staff assist with enrollment.

Reimbursement Support

AfrezzaAssist offers dedicated specialists who can help with benefits verification, prior authorization support, and appeals assistance. This can save significant administrative time for your practice.

Patient Assistance Program

For patients who are uninsured or underinsured and meet income-based eligibility criteria, MannKind may provide Afrezza at no cost through their patient assistance program (PAP). Encourage eligible patients to apply — the enrollment process typically requires proof of income and a prescription.

Third-Party Financial Assistance Resources

Beyond the manufacturer program, several organizations may help patients access insulin affordably:

• NeedyMeds (needymeds.org) — A comprehensive database of patient assistance programs, including manufacturer programs and disease-specific foundations.
• RxAssist (rxassist.org) — Another directory of patient assistance programs with a focus on pharmaceutical manufacturer offerings.
• State pharmaceutical assistance programs (SPAPs) — Many states offer supplemental prescription assistance, particularly for Medicare beneficiaries. Check your state's offerings.
• Diabetes-specific foundations — Organizations such as the American Diabetes Association may offer resources or emergency assistance programs.

Coupon Card Programs and Discount Platforms

While Afrezza is less commonly found on discount card platforms compared to widely-prescribed generics, it is worth checking the following on behalf of your patients:

• SingleCare, GoodRx, and RxSaver — May occasionally show discounted pricing at specific pharmacies
• InsideRx — Often covers brand-name medications
• Optum Perks — Another option to compare pricing

Pricing through these platforms can vary significantly by pharmacy. In some cases, a discount card may offer better pricing than the patient's insurance copay, particularly for patients with high-deductible plans. A good practice is to have staff check both the insurance price and the best available cash/discount price for each patient.

Insurance Optimization Strategies

Benefits Investigation at Prescribing

Before writing the prescription, verify Afrezza coverage through the patient's plan. Many EHR systems offer real-time benefits checking (RTBC) that can show formulary status, estimated copay, PA requirements, and preferred alternatives at the point of prescribing.

Appeal Denied Claims

If a PA is denied, appeal. Include additional clinical documentation, peer-reviewed literature supporting Afrezza's clinical benefits (faster onset, improved postprandial control, reduced hypoglycemia risk), and a letter of medical necessity from the prescriber. AfrezzaAssist can provide support with the appeals process.

Explore Specialty Pharmacy Networks

Some insurance plans offer better pricing through their preferred specialty pharmacy. Check whether the patient's plan has a specialty pharmacy network and whether Afrezza is covered at a lower tier through that channel.

Consider 90-Day Supply

For stable patients, a 90-day supply through mail-order pharmacy may reduce per-unit costs. Many insurance plans offer lower copays for 90-day fills compared to three separate 30-day fills.

Workflow Integration for Your Practice

To systematically help patients with Afrezza costs, consider integrating these steps into your prescribing workflow:

1. At prescribing: Run real-time benefits check; discuss expected costs with the patient
2. If PA required: Submit with comprehensive clinical documentation on the same day
3. At first fill: Enroll patient in AfrezzaAssist co-pay card; check discount platforms for comparison pricing
4. If denied or unaffordable: Appeal the denial; evaluate PAP eligibility; check third-party assistance programs
5. Ongoing: At each visit, ask about medication access and cost concerns; reassess annually as insurance formularies change

Addressing Supply and Availability

Cost is not the only access barrier. Afrezza's single-manufacturer status and specialty nature mean that pharmacy availability can be inconsistent. When patients struggle to find Afrezza in stock, direct them to:

• MedFinder for Providers — Check real-time pharmacy availability
• Specialty pharmacies with established Afrezza supply chains
• MannKind's AfrezzaAssist for pharmacy location assistance

For more on navigating supply challenges, see our provider-focused guides:

• Afrezza Shortage: What Providers Need to Know in 2026
• How to Help Your Patients Find Afrezza in Stock

When Cost Remains Prohibitive: Alternative Approaches

If, despite all efforts, Afrezza remains financially inaccessible for a patient, consider these clinical alternatives:

• Generic insulin lispro or insulin aspart — Authorized generics and biosimilars offer significantly lower costs for rapid-acting insulin coverage.
• Insulin pen devices — For patients whose primary barrier to injection is the syringe/vial process, pen devices may address usability concerns while remaining more affordable.
• Fiasp (insulin aspart) — Offers ultra-rapid onset (closer to Afrezza's profile) in an injectable form.

For a comprehensive look at alternatives, see Alternatives to Afrezza.

Key Takeaways for Providers

• Afrezza costs $550-$650 cash with no generic available — cost is a significant adherence barrier.
• MannKind's AfrezzaAssist offers co-pay cards, reimbursement support, and patient assistance for eligible patients.
• Thorough PA documentation (clinical rationale, prior insulin trials, spirometry results) improves approval rates.
• Compare insurance copay vs. discount card pricing — the lower option varies by patient and plan.
• Integrate cost counseling into your prescribing workflow to catch access issues before they cause non-adherence.
• Use MedFinder to help patients locate pharmacies with Afrezza in stock.